Immunotherapy and targeted therapy for advanced lung neuroendocrine tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three treatments—an immunotherapy drug (Adebrelimab), chemotherapy, and a targeted therapy (Apatinib)—for people with advanced neuroendocrine tumors of the lung. The goal is to see if this combination can shrink or slow the growth of these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a type of lung tumor called a pulmonary neuroendocrine tumor (either large cell, small cell, or atypical carcinoid) that cannot be removed by surgery or has spread to other parts of the body.
- You have not yet had any cancer treatment (like chemotherapy or radiation) for this tumor.
- Your doctor expects you to live at least 3 more months.
- You are generally able to take care of yourself (performance status of 0 to 2).
- You have at least one tumor that can be measured on imaging scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two drugs, adebrelimab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that blocks blood supply to tumors), before surgery can improve outcomes for people with early-stage non-small cell lung cancer. The goal is to shrink the tumor and make surgery more effective.
This trial tests a new combination of two targeted/immune drugs with standard chemotherapy as a first treatment for extensive small cell lung cancer. It aims to see if this approach is safe and effective for people who have not had prior treatment for this cancer.
This trial tests a new combination of drugs (an immunotherapy and a possible new treatment) plus chemotherapy for people with advanced lung cancer. The goal is to see if this combination can shrink tumors or stop them from growing.
This trial tests whether adding an immunotherapy drug called atezolizumab to standard chemotherapy helps people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) that started outside the lung. The goal is to see if the combination works better than chemo alone.
This trial is testing a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) as the first treatment for people with a rare type of cancer called LCNEC or EP-NEC that has spread. The goal is to see if this combination can help shrink or control the cancer and improve outcomes.
This trial tests a combination of immunotherapy (adebrelimab) and chemotherapy (carboplatin/paclitaxel), followed by more immunotherapy, with or without an additional targeted drug (apatinib), for advanced or recurrent endometrial cancer. It aims to see if adding the targeted drug improves outcomes.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.